1. Home
  2. HTO vs MESO Comparison

HTO vs MESO Comparison

Compare HTO & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HTO

H2O America

HOLD

Current Price

$57.37

Market Cap

2.5B

Sector

Utilities

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$14.51

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTO
MESO
Founded
1985
2004
Country
United States
Australia
Employees
837
81
Industry
Water Supply
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HTO
MESO
Price
$57.37
$14.51
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$62.25
N/A
AVG Volume (30 Days)
462.6K
261.0K
Earning Date
04-28-2026
02-26-2026
Dividend Yield
3.02%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.26
$644.56
Revenue Next Year
$7.06
$38.63
P/E Ratio
$17.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$43.75
$9.88
52 Week High
$60.18
$21.50

Technical Indicators

Market Signals
Indicator
HTO
MESO
Relative Strength Index (RSI) 49.36 46.34
Support Level $55.29 $14.44
Resistance Level $59.00 $16.77
Average True Range (ATR) 1.33 0.59
MACD -0.15 0.06
Stochastic Oscillator 38.72 38.13

Price Performance

Historical Comparison
HTO
MESO

About HTO H2O America

H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: